NASDAQ:MGNXMacroGenics Stock Price, Forecast & News

MacroGenics' stock was trading at $6.49 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MGNX shares have increased by 367.8% and is now trading at $30.36. View which stocks have been most impacted by Coronavirus.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 1 sell rating and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MacroGenics.

MacroGenics is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for MacroGenics.

MacroGenics Inc (NASDAQ:MGNX) issued its quarterly earnings results on Tuesday, May, 5th. The biopharmaceutical company reported ($0.91) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($1.01) by $0.10. The biopharmaceutical company had revenue of $13.68 million for the quarter, compared to the consensus estimate of $7.43 million. MacroGenics had a negative net margin of 222.14% and a negative return on equity of 62.43%. View MacroGenics' earnings history.

13 equities research analysts have issued twelve-month price objectives for MacroGenics' shares. Their forecasts range from $6.00 to $50.00. On average, they expect MacroGenics' stock price to reach $29.33 in the next twelve months. This suggests that the stock has a possible downside of 3.4%. View analysts' price targets for MacroGenics.

Media stories about MGNX stock have trended negative this week, according to InfoTrie. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. MacroGenics earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about MacroGenics.

MacroGenics saw a increase in short interest in June. As of June 30th, there was short interest totaling 4,720,000 shares, an increase of 9.0% from the June 15th total of 4,330,000 shares. Based on an average daily volume of 3,180,000 shares, the short-interest ratio is currently 1.5 days. Currently, 10.6% of the company's shares are sold short. View MacroGenics' Current Options Chain.

Some companies that are related to MacroGenics include Reata Pharmaceuticals (RETA), United Therapeutics (UTHR), Ultragenyx Pharmaceutical (RARE), Legend Biotech (LEGN), Mirati Therapeutics (MRTX), Zai Lab (ZLAB), Arrowhead Pharmaceuticals (ARWR), Emergent Biosolutions (EBS), Myokardia (MYOK), Nektar Therapeutics (NKTR), Blueprint Medicines (BPMC), Biohaven Pharmaceutical (BHVN), Global Blood Therapeutics (GBT), Evotec (EVTCY) and GW Pharmaceuticals PLC- (GWPH). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Bausch Health Companies (BHC), Epizyme (EPZM), Incyte (INCY), Karyopharm Therapeutics (KPTI) and Nektar Therapeutics (NKTR).

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

MacroGenics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Diversified Trust Co (0.02%). Company insiders that own MacroGenics stock include Eric Blasius Risser, Jeffrey Stuart Peters, Matthew K Fust and Thomas Spitznagel. View institutional ownership trends for MacroGenics.

MGNX stock was acquired by a variety of institutional investors in the last quarter, including Diversified Trust Co. View insider buying and selling activity for MacroGenics.

Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MGNX stock can currently be purchased for approximately $30.36.

MacroGenics has a market capitalization of $1.49 billion and generates $64.19 million in revenue each year. The biopharmaceutical company earns $-151,810,000.00 in net income (profit) each year or ($3.16) on an earnings per share basis. MacroGenics employs 364 workers across the globe.

The official website for MacroGenics is www.macrogenics.com.

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.